The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002).
The Myelodysplastic Syndromes (MDS) represent a group of potentially acute myeloid leukemic disorders. There exists a delicate balance between increased apoptosis and proliferation of the leukemic hematopoietic stem cell that permits many patients to survive for years. When the balance shifts towards proliferation AML develops with a poor outcome for most but not all patients. I will review the latest proposals from the W.H.O. in classification, including pediatric MDS, prognostic factors and response criteria. Then I will present a strategy for the management of low risk patients with supportive care or low intensity treatment (cytokines, Immune modulation, anti-VEGF agents) and finally chemotherapy and intensive therapy with auto and allo BMT.
Bennett
John M
JM
James P. Wilmot Cancer Center, Rochester, NY, USA.
Kouides
Peter A
PA
Forman
Stephen J
SJ
D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000473:pathology; D019468:Disease Management; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D018570:Risk Assessment